Abstract
The radiochemical synthesis and stability of 67Ga-deferoxamine-folate ([67Ga]Ga-DF-Folate) were examined as a function of DF-Folate concentration. Optimal labeling occurred at DF-Folate concentrations 22.5 μg/mL. To define the possible biological significance of variations in product formulation, the biodistribution of [67Ga]Ga-DF-Folate was examined as a function of administered deferoxamine-folate dose in an athymic mouse KB tumor model. The folate-receptor-positive KB tumors were found to concentrate the 67Ga radiolabel in a dose-dependent fashion, consistent with saturable involvement of the folate receptor in mediating tumor accumulation of the radiopharmaceutical.
Original language | English (US) |
---|---|
Pages (from-to) | 23-25 |
Number of pages | 3 |
Journal | Nuclear Medicine and Biology |
Volume | 26 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1999 |
Keywords
- Ga-Deferoxamine-folate
- Folate receptor
- Tumor-targeting
ASJC Scopus subject areas
- Cancer Research
- Molecular Medicine
- Radiology Nuclear Medicine and imaging